Avoiding rash decisions about zoster vaccination: insights from cost-effectiveness evidence

de Boer and colleagues present a cost-effectiveness analysis based in the Netherlands of two vaccines available for the prevention of herpes zoster. Zostavax┬« was the first vaccine available for the prevention…

Leave a Reply

Your email address will not be published. Required fields are marked *